Compare DYAI & SDEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DYAI | SDEV |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 33.1M |
| IPO Year | 2003 | N/A |
| Metric | DYAI | SDEV |
|---|---|---|
| Price | $0.80 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 309.9K | 114.8K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,090,345.00 | N/A |
| Revenue This Year | $122.79 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $1.09 |
| 52 Week High | $1.35 | $1.27 |
| Indicator | DYAI | SDEV |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | N/A |
| Support Level | $0.69 | N/A |
| Resistance Level | $0.90 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 66.17 | 0.00 |
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.